+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Non-Infectious Macular Edema Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 196 Pages
  • October 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309816
The global market for Non-Infectious Macular Edema Treatment was estimated at US$17.1 Billion in 2023 and is projected to reach US$25.0 Billion by 2030, growing at a CAGR of 5.6% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

What Is Non-Infectious Macular Edema and Why Is Treatment Essential?

Non-infectious macular edema is a condition characterized by the accumulation of fluid in the macula, the central part of the retina responsible for sharp vision. This condition is commonly associated with diseases such as diabetic retinopathy, uveitis, and retinal vein occlusion (RVO), and leads to blurred or distorted vision if left untreated. Treatment for non-infectious macular edema includes corticosteroids, anti-vascular endothelial growth factor (anti-VEGF) injections, non-steroidal anti-inflammatory drugs (NSAIDs), and laser therapy, all aimed at reducing fluid buildup, inflammation, and preventing vision loss.

The importance of treating non-infectious macular edema lies in its ability to preserve vision and prevent complications such as permanent blindness. Early and effective treatment is crucial for maintaining quality of life, especially for patients with underlying chronic conditions like diabetes. The treatment landscape has advanced significantly with the introduction of anti-VEGF therapies, which specifically target the abnormal blood vessels that contribute to fluid leakage and macular swelling, offering patients better outcomes and fewer side effects than traditional treatments.

How Is the Non-Infectious Macular Edema Treatment Market Evolving?

The non-infectious macular edema treatment market is evolving with the increasing availability of targeted biologic therapies such as anti-VEGF injections, which have become the standard of care for many patients. One key trend is the growing use of these biologics, including ranibizumab and aflibercept, which are designed to inhibit the growth of abnormal blood vessels and reduce fluid leakage in the retina. These therapies are proving to be highly effective in improving vision and reducing the need for more invasive treatments, such as laser therapy or surgery.

Another significant trend is the development of long-acting corticosteroid implants and sustained-release drug delivery systems. These innovations reduce the frequency of treatments, offering patients more convenience and better adherence to their treatment regimens. Additionally, advancements in imaging technologies, such as optical coherence tomography (OCT), are improving the diagnosis and monitoring of macular edema, enabling more precise and individualized treatment approaches. As researchers continue to explore new therapies targeting inflammation and fluid accumulation, the market is expected to expand with more options for patients.

Which Patient Groups Are Driving the Demand for Macular Edema Treatment?

The demand for non-infectious macular edema treatments is largely driven by patients with underlying chronic conditions that increase the risk of macular edema, particularly individuals with diabetic retinopathy. As diabetes becomes more prevalent globally, the incidence of diabetic macular edema is rising, leading to higher demand for effective therapies. Similarly, patients with retinal vein occlusion (RVO), a condition that can cause fluid accumulation in the retina, are significant users of macular edema treatments.

Another key patient group includes individuals with uveitis, an inflammatory disease of the eye that can lead to macular edema. These patients often require corticosteroids or immunosuppressive therapies to manage inflammation and prevent vision loss. The aging population is also a key driver of demand, as older adults are more likely to experience macular edema due to age-related retinal conditions. Early diagnosis and timely treatment are critical for these patients to preserve vision and maintain independence.

What Are the Key Growth Drivers in the Non-Infectious Macular Edema Treatment Market?

The growth in the non-infectious macular edema treatment market is driven by several key factors, starting with the rising prevalence of diabetes and associated retinal complications like diabetic macular edema. As more people are diagnosed with diabetes worldwide, the need for effective treatments for macular edema is increasing. Another critical driver is the widespread adoption of anti-VEGF therapies, which have significantly improved outcomes for patients with macular edema by reducing fluid accumulation and improving vision.

Technological advancements in drug delivery systems, such as sustained-release implants, are also fueling market growth by providing longer-lasting treatments and reducing the burden of frequent injections. Additionally, the aging population is contributing to the demand for macular edema therapies, as age-related eye conditions become more common. The increasing focus on early diagnosis and treatment, supported by advanced imaging techniques like optical coherence tomography (OCT), is further driving market expansion by enabling more precise and effective treatment strategies.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Anti-VEGF Drug segment, which is expected to reach US$16.6 Billion by 2030 with a CAGR of a 5.3%. The Corticosteroids Drug segment is also set to grow at 6.7% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was valued at $4.6 Billion in 2023, and China, forecasted to grow at an impressive 5.2% CAGR to reach $3.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Non-Infectious Macular Edema Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Non-Infectious Macular Edema Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Non-Infectious Macular Edema Treatment Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AbbVie, Inc., Alimera Sciences, Inc., Allergan PLC, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 46 Featured):

  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Allergan PLC
  • Amgen, Inc.
  • Bausch Health Companies, Inc.
  • Bayer AG
  • Clearside Biomedical, Inc.
  • F. Hoffmann-La Roche AG
  • Novartis International AG
  • Pfizer, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Non-Infectious Macular Edema Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Non-Infectious Macular Edema (NIME) Fuels Demand for Advanced Treatment Solutions
  • Increasing Adoption of Anti-VEGF Therapies Expands Market for Effective Non-Infectious Macular Edema Treatments
  • Growing Use of Corticosteroid Implants Strengthens Market for Long-Term Control of Non-Infectious Macular Edema
  • Technological Advancements in Ophthalmic Drug Delivery Propel Growth in Sustained-Release Treatment Options for NIME
  • Rising Focus on Minimally Invasive Treatments Expands Opportunities for Intraocular Injections and Implants in NIME
  • Growing Adoption of Combination Therapies in NIME Expands Market for Multi-Modal Treatment Approaches
  • Increasing Focus on Retinal Imaging and Diagnostic Tools Fuels Growth in Early Detection and Monitoring of Non-Infectious Macular Edema
  • Rising Use of Personalized Medicine and Genetic Testing Expands Opportunities for Targeted NIME Therapies
  • Growing Use of Anti-Inflammatory Agents in Non-Infectious Macular Edema Expands Market for Corticosteroid and Immunosuppressant Therapies
  • Increasing Focus on Drug-Resistant Non-Infectious Macular Edema Expands Market for Innovative Treatment Solutions
  • Technological Developments in Nanotechnology Propel Growth in Non-Infectious Macular Edema Drug Delivery Systems
  • Rising Demand for Biologics in Non-Infectious Macular Edema Treatment Strengthens Market for Advanced Therapeutics
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Non-Infectious Macular Edema Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Non-Infectious Macular Edema Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Non-Infectious Macular Edema Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Non-Infectious Macular Edema Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Anti-VEGF by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Immunosuppressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Non-Infectious Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 21: USA Historic Review for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: USA 16-Year Perspective for Non-Infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types for the Years 2014, 2024 & 2030
CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 24: Canada Historic Review for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: Canada 16-Year Perspective for Non-Infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types for the Years 2014, 2024 & 2030
JAPAN
  • Non-Infectious Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 26: Japan Recent Past, Current & Future Analysis for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: Japan Historic Review for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: Japan 16-Year Perspective for Non-Infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types for the Years 2014, 2024 & 2030
CHINA
  • Non-Infectious Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 29: China Recent Past, Current & Future Analysis for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: China Historic Review for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: China 16-Year Perspective for Non-Infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types for the Years 2014, 2024 & 2030
EUROPE
  • Non-Infectious Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 32: Europe Recent Past, Current & Future Analysis for Non-Infectious Macular Edema Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 33: Europe Historic Review for Non-Infectious Macular Edema Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: Europe 16-Year Perspective for Non-Infectious Macular Edema Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 35: Europe Recent Past, Current & Future Analysis for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: Europe Historic Review for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Europe 16-Year Perspective for Non-Infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types for the Years 2014, 2024 & 2030
FRANCE
  • Non-Infectious Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 38: France Recent Past, Current & Future Analysis for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: France Historic Review for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: France 16-Year Perspective for Non-Infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types for the Years 2014, 2024 & 2030
GERMANY
  • Non-Infectious Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 41: Germany Recent Past, Current & Future Analysis for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: Germany Historic Review for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Germany 16-Year Perspective for Non-Infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types for the Years 2014, 2024 & 2030
ITALY
  • Table 44: Italy Recent Past, Current & Future Analysis for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Italy Historic Review for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Italy 16-Year Perspective for Non-Infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Non-Infectious Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 47: UK Recent Past, Current & Future Analysis for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: UK Historic Review for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: UK 16-Year Perspective for Non-Infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 50: Rest of Europe Recent Past, Current & Future Analysis for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: Rest of Europe Historic Review for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: Rest of Europe 16-Year Perspective for Non-Infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Non-Infectious Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 53: Asia-Pacific Recent Past, Current & Future Analysis for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: Asia-Pacific Historic Review for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: Asia-Pacific 16-Year Perspective for Non-Infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types for the Years 2014, 2024 & 2030
REST OF WORLD
  • Table 56: Rest of World Recent Past, Current & Future Analysis for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Rest of World Historic Review for Non-Infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Rest of World 16-Year Perspective for Non-Infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics and Other Drug Types for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Allergan PLC
  • Amgen, Inc.
  • Bausch Health Companies, Inc.
  • Bayer AG
  • Clearside Biomedical, Inc.
  • F. Hoffmann-La Roche AG
  • Novartis International AG
  • Pfizer, Inc.

Table Information